Omada Health Presents AI-Powered Meal Feedback Research and 12-Month GLP-1 Care Track Outcomes at ObesityWeek 2026
Omada’s AI-powered Meal Map tool, built to focus on nutrient quality rather than restrictive eating, helped members build meal-tracking habits linked to greater weight loss at week 16.
In Omada’s GLP-1 Care Track, 71% of members stayed on their medication for a full year, and those who did lost 18.4% of body weight, comparable to clinical trials.
SAN FRANCISCO – November 14, 2026 – Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, announced two presentations at ObesityWeek 2026, taking place November 14-17, 2026, in Washington, D.C. The research looks at the support people need between doctor visits, including building food habits that fit daily life and staying on GLP-1 treatment for a full year to get the most out of the medication.
Poster Presentation #308: AI-Powered Meal Feedback Is Linked to More Meal Tracking and Greater Weight Loss in a Virtual Lifestyle Program
The first presentation highlights how Omada’s AI-powered tool, Meal Map, may help people who struggle with emotional eating and cravings build tracking habits that support weight loss.1 Meal Map, now available in Omada’s cardiometabolic programs, provides members with real-time, AI-powered feedback on every meal logged, focusing on nutrient quality rather than restrictive eating. Instead of scoring foods as “good” or “bad,” AI technology identifies the nutrient-dense parts of a meal and the gaps in its balance alongside actionable guidance for future meals.
In this analysis, 13,852 members who joined Omada’s behavior change program between September and November 2025 and reported emotional eating, trouble managing cravings or snacking often were randomized into two groups. The control group received Omada’s core nutrition features, including meal tracking, care team alerts when nutrition patterns changed, and the OmadaSpark chatbot, an AI-powered resource for nutrition education. The second group received those same features plus Meal Map.1
Compared with the control group, Meal Map members1:
- Were more likely to track at least three meals in their first month (41.1% vs. 36.0%).
- Had 34% greater odds of tracking at least three meals every month through 16 weeks.
- Lost more weight at week 16 if they tracked at least three meals in their first month (3.47% vs. 3.02%).
Jeanean B. Naqvi, PhD, Clinical Research Scientist, and Alison Megliola, MS, RD, CDCES, Director of Clinical Product, will present the poster on Saturday, November 14, 2026, from 7:30 to 8:30 PM ET at ObesityWeek 2026.
Poster Presentation #533: Virtual Lifestyle Program Support for GLP-1 Therapy: 12-Month Persistence and Weight Outcomes in Adults With Obesity
The second presentation builds on 12-month GLP-1 Care Track results Omada shared in January 2026.2 The analysis included 969 adults without diabetes who started a GLP-1 between 60 days before and 30 days after enrolling in Omada’s GLP-1 Care Track between June and September 2024. Medication persistence was confirmed through pharmacy claims.3
Key findings include3:
- 71% stayed on GLP-1 medication at 52 weeks after their first fill.
- Members who stayed on medication the full year lost an average of 18.4% of body weight, comparable to clinical trial outcomes (approximately 16-17% with semaglutide and approximately 20% with tirzepatide),4,5 and the full cohort lost an average of 16.3% of body weight at 12 months regardless of time on medication.
- Each additional five weekly engagement actions was associated with 28% greater adjusted odds of staying on medication and, among those who stayed on, 28% greater odds of reaching 15% weight loss.
- Among members who stopped medication, early findings suggested potential for weight maintenance after discontinuation.
Omada’s GLP-1 Care Track supports members taking GLP-1s between doctor visits, and if they stop, helps with the transition off medication. Each member works with a dedicated care team to receive ongoing support on side effects, medication questions and GLP-1-specific nutrition, along with access to GLP-1 peer communities and digital tools for meal logging, behavior tracking and nutrition. Members also have access to an exercise specialist and customized plans to maintain lean mass. In this analysis, members who engaged with Omada’s support more often were more likely to stay on their medication.
“Patients often leave a doctor’s visit with good advice about how to eat, and then they have to make it work on their own until the next appointment,” said Thomas Tsang, MD, MPH, Chief Medical Officer at Omada Health. “That’s harder for people who deal with emotional eating or cravings, because those moments rarely happen in the exam room. Feedback right after a meal is logged gives them support when they need it. Across both analyses, members who stayed engaged between visits did better, whether that meant building a tracking habit or staying on a GLP-1 for a full year.”
The GLP-1 Care Track analysis was completed as part of the Omada Insights Lab ANSWERS (ANalyzing Success of WEight medication with Real-world evidence and Stats) Initiative, which examines and shares real-world data from Omada’s behavior change weight health programs.
Omada Health’s Senior Clinical Research Scientist, Susan M. Devaraj, PhD, MS, RD, will present the analysis on Sunday, November 15, 2026, from 2:30 to 3:30 PM ET at ObesityWeek 2026.
.png)
